Bactericidal and Bacteriostatic Agents against Drug-Resistant Bacteria

Back to all technologies
Download as PDF
2019-SINT-68535
Researchers at Purdue University have developed novel antimicrobial agents to solve the continued problem of drug-resistant bacterial strains; approximately 20,000 people die in the US every year from drug-resistant infections. These antimicrobial agents potently inhibit bacterial growth in several species, including drug-resistant strains, at concentrations as low as 0.0675 micrograms per milliliter. This family of compounds contains both bactericidal and bacteriostatic agents.

Advantages:
-Inhibits drug resistant bacteria strains
-Kills bacteria at low concentration

Potential Applications:
-Antimicrobial Agent



Related Publication:
Potent trifluoromethoxy, trifluoromethylsulfonyl, trifluoromethylthio and pentafluorosulfanyl containing (1,3,4-oxadiazol-2-yl)benzamides against drug-resistant Gram-positive bacteria
RSC Med. Chem., 2020,11, 102-110
DOI: 10.1039/C9MD00391F
Apr 24, 2020
PCT-Patent
WO
(None)
(None)

Apr 26, 2019
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org